Segment & Geographic Data
Quant-Grade Normalized Data
API & CSV Delivery
Collplant Biotechnologies Ltd's Business Segments
Collplant Biotechnologies Ltd's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of 2025 ((Dec 31 2025))
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 2
Regions Reported
1
Annual Results
Revenue Share by Region -
- Europe and Other4.1%
Revenue by Geographic Region -
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| Europe and Other | $ 0 | 4.1% |
Revenue by Product & Service Category -
- Revenues From Milestones84.4%
- Revenues From Sales of Goods15.6%
Revenue by Product & Service Category -
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Revenues From Milestones | $ 2 | 84.4% |
| Revenues From Sales of Goods | $ 0 | 15.6% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Collplant Biotechnologies Ltd
Collplant Biotechnologies Ltd is an Israeli company specializing in the development and commercialization of innovative technologies and products derived from its proprietary plant-based collagen manufacturing platform. The company's focus is on the fast-growing fields of regenerative medicine, tissue engineering, and aesthetic medicine.
Collagen, a protein that provides support and structure to tissues, is widely used in medical and cosmetic applications. However, the traditional sources of collagen, such as animal-derived sources (such as bovine and porcine), suffer from limitations such as risk of contamination, potential transmission of diseases, and availability concerns. Collplant's solution is to use tobacco plants as a sustainable, cost-effective, and bio-safe source of recombinant human collagen.
The company's proprietary plant-based expression platform, known as the hCollagen Plant, has been engineered to produce identical human collagen to promote better integration and functionality within the human body. This breakthrough technology enables the production of pure, safe, and effective recombinant human collagen at commercial scales.
Collplant's portfolio includes a range of products and product candidates that harness the potential of this plant-based collagen. One of their most promising products is the Vergenix STR, a bioactive wound care product for the treatment of chronic wounds such as diabetic foot ulcers and venous leg ulcers. Vergenix STR is a gel formulation that promotes optimal wound healing through the release of endogenous growth factors and cytokines, which stimulate cell migration, proliferation, and tissue remodeling. This product has demonstrated promising results in clinical trials and has received regulatory approvals in multiple countries.
In addition to wound care, Collplant is actively exploring other therapeutic applications of its plant-based collagen, such as regenerative medicine for tendon and ligament repair, bone grafts, and cartilage reconstruction. The company is also developing a range of aesthetic medicine products, including dermal fillers and bioengineered skin substitutes, to address the growing demand for natural and safe solutions in the cosmetic field.
Collplant has established collaborations and partnerships with leading academic institutions, medical centers, and industry players to advance its technology and broaden its product pipeline. The company operates manufacturing facilities in Israel and is actively expanding its global commercial reach through distribution agreements and strategic alliances.
Overall, Collplant Biotechnologies Ltd is at the forefront of plant-based collagen manufacturing and is poised to revolutionize various fields of medicine and cosmetic applications with its innovative and sustainable solutions.
Collagen, a protein that provides support and structure to tissues, is widely used in medical and cosmetic applications. However, the traditional sources of collagen, such as animal-derived sources (such as bovine and porcine), suffer from limitations such as risk of contamination, potential transmission of diseases, and availability concerns. Collplant's solution is to use tobacco plants as a sustainable, cost-effective, and bio-safe source of recombinant human collagen.
The company's proprietary plant-based expression platform, known as the hCollagen Plant, has been engineered to produce identical human collagen to promote better integration and functionality within the human body. This breakthrough technology enables the production of pure, safe, and effective recombinant human collagen at commercial scales.
Collplant's portfolio includes a range of products and product candidates that harness the potential of this plant-based collagen. One of their most promising products is the Vergenix STR, a bioactive wound care product for the treatment of chronic wounds such as diabetic foot ulcers and venous leg ulcers. Vergenix STR is a gel formulation that promotes optimal wound healing through the release of endogenous growth factors and cytokines, which stimulate cell migration, proliferation, and tissue remodeling. This product has demonstrated promising results in clinical trials and has received regulatory approvals in multiple countries.
In addition to wound care, Collplant is actively exploring other therapeutic applications of its plant-based collagen, such as regenerative medicine for tendon and ligament repair, bone grafts, and cartilage reconstruction. The company is also developing a range of aesthetic medicine products, including dermal fillers and bioengineered skin substitutes, to address the growing demand for natural and safe solutions in the cosmetic field.
Collplant has established collaborations and partnerships with leading academic institutions, medical centers, and industry players to advance its technology and broaden its product pipeline. The company operates manufacturing facilities in Israel and is actively expanding its global commercial reach through distribution agreements and strategic alliances.
Overall, Collplant Biotechnologies Ltd is at the forefront of plant-based collagen manufacturing and is poised to revolutionize various fields of medicine and cosmetic applications with its innovative and sustainable solutions.
Collplant Biotechnologies Ltd is a regenerative medicine company that focuses on developing innovative solutions for tissue repair and regeneration. The company primarily leverages its proprietary plant-based recombinant collagen technology to create products and services across various segments in the medical and pharmaceutical fields. Below are detailed segments, products, and services offered by Collplant:
1. Wound Healing Products
Collplants product offerings in this segment aim to enhance the healing process of wounds, particularly in chronic wounds and burns.
- Collagen-based Dressings: These are advanced dressings that utilize recombinant collagen derived from plants. The dressings provide a conducive environment for wound healing, support cellular activities, and enhance the tissue regeneration process.
- Bioengineered Skin Substitutes: Developed for more severe wounds, these substitutes are designed to mimic natural skin, providing a matrix for cellular infiltration and new tissue formation. These products are especially beneficial for diabetic foot ulcers and venous leg ulcers.
Tissue Regeneration
Collplant is also active in the development of products aimed at promoting the regeneration of various types of tissues beyond skin.
- Collagen-based Injectable Gels: These gels can be injected into damaged tissues to provide structural support and enhance healing, particularly in orthopedic applications. They serve as scaffolds for new tissue growth, facilitating the recovery of musculoskeletal injuries.
- Soft Tissue Reconstruction Products: Targeting aesthetic and reconstructive surgery, these products facilitate the replacement or augmentation of soft tissues, providing solutions for both cosmetic enhancement and reconstructive needs post-surgery or injury.
Orthopedic Applications
Collplant is exploring the use of its collagen technology in orthopedic treatments, specifically for joint and cartilage repair.
- Injectable Cartilage Regeneration Solutions: These products are designed to support the repair of cartilage lesions and joint degeneration, potentially reducing the need for invasive procedures like joint replacements. The injectable formulations offer an innovative approach to treating osteoarthritis and other degenerative joint diseases.
Dental Applications
In the field of dentistry, Collplant offers solutions that aim to enhance oral health and support procedures like bone regeneration and periodontal treatment.
- Guided Bone Regeneration Products: Utilizing recombinant collagen, these offerings support bone healing and regeneration in dental implant procedures. They allow for a scaffold to be created that fosters bone growth, crucial in areas where bone density is insufficient.
- Bone Graft Substitutes: Aimed at providing alternatives to traditional autograft procedures, these substitutes help in the regeneration of bone in dental surgeries such as implants and reconstructive procedures.
Research and Development Services
Collplant also engages in R&D ventures that cater to both internal projects and partnerships with external entities in the biotechnology and pharmaceutical sectors.
- Custom Collagen Formulations: The company provides custom solutions to other biotech firms or research institutions developing new therapeutics or regenerative therapies, taking advantage of its proprietary collagen technology.
- Collagen-based Bioprinting Applications: Exploring the use of its collagen in 3D bioprinting, Collplant enables the creation of complex tissue structures for research, therapeutic testing, and potential future applications in organ regrowth.
Partnerships and Collaborations
Collplant is active in forming strategic partnerships with other companies, academic institutions, and healthcare organizations to expand its technologies and integrate its products into broader therapeutic approaches.
- Co-development Agreements: Collaborating with pharmaceutical companies to develop specific applications of its collagen technology, facilitating the integration of regenerative medicine into conventional treatments.
- Clinical Trials: Engaging in partnerships to conduct clinical trials, assessing the efficacy of its product offerings in real-world settings and further validating its technologies.
Regulatory and Compliance Expertise
As a biotechnology firm, Collplant places significant emphasis on meeting regulatory standards and ensuring compliance with international health authorities.
- Regulatory Support Services: Offering consultation and support for navigating the complex regulatory pathways necessary for bringing new medical products to market, including submissions to the FDA and other regulatory bodies.
Through these extensive offerings, Collplant Biotechnologies Ltd aims to establish itself as a leader in regenerative medicine, emphasizing the therapeutic potential of plant-based recombinant collagen in promoting healing and tissue regeneration across various medical fields.
1. Wound Healing Products
Collplants product offerings in this segment aim to enhance the healing process of wounds, particularly in chronic wounds and burns.
- Collagen-based Dressings: These are advanced dressings that utilize recombinant collagen derived from plants. The dressings provide a conducive environment for wound healing, support cellular activities, and enhance the tissue regeneration process.
- Bioengineered Skin Substitutes: Developed for more severe wounds, these substitutes are designed to mimic natural skin, providing a matrix for cellular infiltration and new tissue formation. These products are especially beneficial for diabetic foot ulcers and venous leg ulcers.
Tissue Regeneration
Collplant is also active in the development of products aimed at promoting the regeneration of various types of tissues beyond skin.
- Collagen-based Injectable Gels: These gels can be injected into damaged tissues to provide structural support and enhance healing, particularly in orthopedic applications. They serve as scaffolds for new tissue growth, facilitating the recovery of musculoskeletal injuries.
- Soft Tissue Reconstruction Products: Targeting aesthetic and reconstructive surgery, these products facilitate the replacement or augmentation of soft tissues, providing solutions for both cosmetic enhancement and reconstructive needs post-surgery or injury.
Orthopedic Applications
Collplant is exploring the use of its collagen technology in orthopedic treatments, specifically for joint and cartilage repair.
- Injectable Cartilage Regeneration Solutions: These products are designed to support the repair of cartilage lesions and joint degeneration, potentially reducing the need for invasive procedures like joint replacements. The injectable formulations offer an innovative approach to treating osteoarthritis and other degenerative joint diseases.
Dental Applications
In the field of dentistry, Collplant offers solutions that aim to enhance oral health and support procedures like bone regeneration and periodontal treatment.
- Guided Bone Regeneration Products: Utilizing recombinant collagen, these offerings support bone healing and regeneration in dental implant procedures. They allow for a scaffold to be created that fosters bone growth, crucial in areas where bone density is insufficient.
- Bone Graft Substitutes: Aimed at providing alternatives to traditional autograft procedures, these substitutes help in the regeneration of bone in dental surgeries such as implants and reconstructive procedures.
Research and Development Services
Collplant also engages in R&D ventures that cater to both internal projects and partnerships with external entities in the biotechnology and pharmaceutical sectors.
- Custom Collagen Formulations: The company provides custom solutions to other biotech firms or research institutions developing new therapeutics or regenerative therapies, taking advantage of its proprietary collagen technology.
- Collagen-based Bioprinting Applications: Exploring the use of its collagen in 3D bioprinting, Collplant enables the creation of complex tissue structures for research, therapeutic testing, and potential future applications in organ regrowth.
Partnerships and Collaborations
Collplant is active in forming strategic partnerships with other companies, academic institutions, and healthcare organizations to expand its technologies and integrate its products into broader therapeutic approaches.
- Co-development Agreements: Collaborating with pharmaceutical companies to develop specific applications of its collagen technology, facilitating the integration of regenerative medicine into conventional treatments.
- Clinical Trials: Engaging in partnerships to conduct clinical trials, assessing the efficacy of its product offerings in real-world settings and further validating its technologies.
Regulatory and Compliance Expertise
As a biotechnology firm, Collplant places significant emphasis on meeting regulatory standards and ensuring compliance with international health authorities.
- Regulatory Support Services: Offering consultation and support for navigating the complex regulatory pathways necessary for bringing new medical products to market, including submissions to the FDA and other regulatory bodies.
Through these extensive offerings, Collplant Biotechnologies Ltd aims to establish itself as a leader in regenerative medicine, emphasizing the therapeutic potential of plant-based recombinant collagen in promoting healing and tissue regeneration across various medical fields.